
Teva Pharmaceutical (TEVA) Stock Forecast & Price Target
Teva Pharmaceutical (TEVA) Analyst Ratings
Bulls say
Teva Pharmaceutical Industries has demonstrated a robust performance in its generics segment, which is expected to generate $9.5 billion in global sales for 2024, representing 57% of the company's total revenue, an increase from 55% in 2023. The company has also achieved notable geographic expansion, with non-US sales growing by 5.3% year-over-year in 2024, highlighting a strong international market presence and the ongoing rollout of products like Ajovy and Austedo in multiple countries. Additionally, European sales accounted for 31% of revenues, and international sales rose from 13% in 2022 to 15%, indicating a positive trajectory for overall sales diversification.
Bears say
Teva Pharmaceutical Industries has experienced significant challenges, as indicated by a substantial decline in US sales for affected products, which represented only 4% of the company's total US sales in 2024, reflecting a troubling trend since 2020. Additionally, the company's active pharmaceutical ingredient (API) segment reported a notable 16% decline in third-party sales in 2023, despite an overall 6% increase in total sales, highlighting issues related to generic oversupply and margin erosion. These factors contributed to a 13% year-over-year decline in US generic sales for the quarter, underscoring a concerning outlook for Teva's core business performance.
This aggregate rating is based on analysts' research of Teva Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.
Teva Pharmaceutical (TEVA) Analyst Forecast & Price Prediction
Start investing in Teva Pharmaceutical (TEVA)
Order type
Buy in
Order amount
Est. shares
0 shares